Related Experiment Video
Updated: Jun 27, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Future diagnostic agents
Filip Gemmel1, Nicolas Dumarey, Mick Welling
1Department of Nuclear Medicine, KCL, Medical Center, Leeuwarden, The Netherlands. f.gemmel@chello.nl
Abstract:
Timely and specific diagnosis of infectious diseases can be clinically challenging but essential for the patient's outcome. Laboratory tests, such as a blood culture or urine specimen, can detect the responsible micro-organism but cannot discriminate between sterile inflammatory disease and truly infectious disease. Imaging tests, like scintigraphic techniques, can pinpoint the infection in the body. There are a number of clinical scintigraphic tests from which to choose, and no single test is optimal for the various presentations of clinical infectious disease. The currently available radiopharmaceuticals often are not capable of distinguishing between sterile inflammation, and bacterial or fungal infections. Neutrophil-mediated processes, characteristic for both inflammatory and infectious processes, can be targeted in situ by radiolabeled leukocytes, antibodies or fragments, or even by cytokines and (18)F-fluorodeoxyglucose. Unfortunately those techniques are not infection-specific markers, and ongoing research is in progress to tackle this problem. The most promising option in this respect is directly targeting bacteria or fungi with radiolabeled antibiotics or antimicrobial peptides. These theoretically highly infection-specific radiopharmaceuticals could be used for monitoring the success of antimicrobial therapy of infectious disease. Although results from preclinical experiments and pilot studies in patients are promising, radiolabeled anti-infective agents are not currently in routine clinical use and studies are continuing to prove their effectiveness for diagnostic imaging of infections in the future.
Insights
Diagnosing infections is challenging. New radiopharmaceuticals targeting microbes show promise for infection imaging and therapy monitoring, though clinical use is still under investigation.
Area of Science:
- Nuclear medicine
- Infectious disease diagnostics
- Radiopharmaceutical development
Background:
- Accurate diagnosis of infectious diseases is crucial but challenging.
- Current laboratory and imaging tests have limitations in differentiating infection from sterile inflammation.
- Existing radiopharmaceuticals often lack specificity for bacterial or fungal infections.
Purpose of the Study:
- To review the current state and future potential of diagnostic imaging in infectious diseases.
- To highlight the limitations of existing scintigraphic techniques and radiopharmaceuticals.
- To explore novel radiolabeled anti-infective agents for specific infection detection.
Main Methods:
- Review of current diagnostic modalities including laboratory and imaging tests.
- Discussion of radiopharmaceuticals targeting neutrophil-mediated processes.
- Exploration of novel approaches using radiolabeled antibiotics and antimicrobial peptides.
Main Results:
- Neutrophil-targeting agents can indicate inflammation but are not infection-specific.
- Radiolabeled anti-infective agents show promise in preclinical and pilot studies.
- These novel agents could potentially monitor antimicrobial therapy success.
Conclusions:
- Directly targeting pathogens with radiolabeled anti-infectives is a promising strategy for infection-specific imaging.
- Further research and clinical studies are needed to establish the efficacy of these agents in routine practice.
- Radiolabeled anti-infective agents represent a potential advancement in diagnosing and managing infectious diseases.
